Chapter 10 of 25
- I: within cervix
- II: beyond uterus, not lower vagina or pelvic wall
- III: lower vagina, pelvic wall, kidneys or regional nodes
- IV: adjacent organ mucosa or distant disease
What you will learn
Understand stages and substages; interpret lymph-node suffixes; recognize why different staging editions cannot be exchanged casually.
Stage-by-stage reference
| Stage | Patient-friendly definition |
|---|---|
| I | Confined to the cervix; extension to the uterine body is disregarded for this classification |
| IA | Invasion detectable only microscopically, no more than 5 mm deep |
| IA1 | Invasion no more than 3 mm deep |
| IA2 | Invasion more than 3 mm and no more than 5 mm deep |
| IB | Invasion deeper than 5 mm, still confined to the cervix |
| IB1 | Tumour no more than 2 cm in greatest dimension |
| IB2 | More than 2 cm and no more than 4 cm |
| IB3 | More than 4 cm |
| II | Beyond the uterus, but not the lower third of vagina or pelvic wall |
| IIA1 / IIA2 | Upper two-thirds vaginal involvement without parametrial invasion; no more than 4 cm / more than 4 cm |
| IIB | Parametrial involvement without reaching the pelvic wall |
| IIIA | Lower-third vaginal involvement without pelvic-wall extension |
| IIIB | Pelvic-wall extension and/or tumour-related hydronephrosis or a nonfunctioning kidney |
| IIIC1 | Pelvic lymph-node metastasis |
| IIIC2 | Para-aortic lymph-node metastasis |
| IVA | Spread to adjacent pelvic organs, including confirmed bladder or rectal mucosal involvement |
| IVB | Distant spread, such as distant organs or nonregional nodes |
How stage is established
Examination, imaging and pathology may all contribute. Pathological findings take precedence when available. For IIIC, “r” indicates imaging-based nodal staging and “p” indicates pathological confirmation. Micrometastases count as nodal disease; isolated tumour cells alone do not change the stage. A clinician must interpret the full report, including deposit size and location.
Lymphovascular space invasion means cancer cells are seen in small vessels. It can affect treatment choices but does not by itself change the FIGO stage. Likewise, grade and tumour biomarkers are different from stage. Tumour-related kidney obstruction has a staging role; obstruction from an unrelated cause should not be automatically attributed to the cancer.
Important boundaries and limitations
A microscopic depth of exactly 3 mm lies in IA1 in the corrected framework, and exactly 5 mm in IA2. For stage IB size divisions, exactly 2 cm lies in IB1 and exactly 4 cm in IB2. These measurements require appropriate pathological or clinical assessment; they are not measurements a patient should infer from symptoms or a photograph.
Swelling of the bladder lining alone does not establish IVA. The team may need direct examination and biopsy when mucosal invasion is suspected. Regional nodes do not automatically mean IVB. Two people labelled IIIC can have quite different primary tumours and outlooks, so stage must be interpreted with the complete disease pattern.
Stage and treatment are related, not identical
Very early disease may be treated surgically, sometimes preserving fertility. Larger or locally advanced disease commonly needs chemoradiation and brachytherapy. Selected high-risk patients may also receive immunotherapy under the relevant regional indication. IVB usually requires systemic treatment and symptom-directed care, with local approaches considered selectively. Stage alone cannot select the exact regimen.
Misconception and common question
“Stage III always means distant metastases” is false. Why does an immunotherapy label mention FIGO 2014? It reflects the trial and approval framework; clinicians must map the actual disease extent, not simply substitute a FIGO 2018 number.
Take-home messages
Ask for stage, edition and supporting findings. Use the stage explorer to learn definitions, not to stage yourself. Request an explanation of both local tumour extent and nodal status.
References and review status
- Bhatla et al. Cancer of the cervix uteri: FIGO Cancer Report 2025
- NCI — Cervical cancer stages
- FDA — Pembrolizumab with chemoradiotherapy, FIGO 2014 III–IVA, January 2024
Evidence/editorial check: 28 October 2026. AI-assisted preparation is separate from physician sign-off. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy